PIM
ESPR

Partner Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Partner Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,722
Closed -$731K – 78
2019
Q2 		$731K Sell
15,722
-3,125
-17% -$147K 0.78% 45
2019
Q1 		$757K Sell
18,847
-6,494
-26% -$291K 0.87% 44
2018
Q4 		$1.17M Sell
25,341
-99
-0.4% -$4.77K 1.46% 23
2018
Q3 		$1.13M Sell
25,440
-6,808
-21% -$313K 0.86% 49
2018
Q2 		$1.26M Buy
32,248
+16,138
+100% +$815K 1.02% 35
2018
Q1 		$1.17M Buy
16,110
+3,970
+33% +$292K 1.26% 32
2017
Q4 		$799K Buy
12,140
+3,021
+33% +$163K 0.92% 42
2017
Q3 		$457K Buy
9,119
+5,096
+127% +$246K 0.43% 62
2017
Q2 		$186K Buy
+4,023
New +$148K 0.25% 77

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Partner Investment Management's ESPR Position: Q3 2019 in Review

Partner Investment Management sold out of Esperion Therapeutics (ESPR) in Q3 2019, closing a stake of 15,722 shares — an estimated $731K sold.

Partner Investment Management first reported a position in ESPR in Q2 2017 and held it in 9 quarters. The position peaked at $1.26M in Q2 2018. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

  • Partner Investment Management reported no remaining Esperion Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Partner Investment Management sold 15,722 Esperion Therapeutics shares in Q3 2019, an estimated $731K.
  • Partner Investment Management first reported a position in Esperion Therapeutics in Q2 2017 and held it in 9 quarters.
  • Partner Investment Management's Esperion Therapeutics position peaked at $1.26M in Q2 2018.
  • 152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Partner Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.